about
Prostate cancer: ESMO Consensus Conference Guidelines 2012The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02).Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).'Act on oncology' as a new comprehensive approach to assess prostate cancer centres--method description and results of a pilot studyMultidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate CancermiR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.Cancer of the prostate.Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activationVaccination therapy in prostate cancer.Early breast cancer irradiation after conservative surgery: quality control by portal localization films.Quality assurance of 3D-CRT: indications and difficulties in their applications.Predictive models of toxicity in external radiotherapy: dosimetric issues.Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues.Multipeptide vaccination in cancer patients.miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts.Dose-volume effects for normal tissues in external radiotherapy: pelvis.Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.Reducing rectal injury during external beam radiotherapy for prostate cancer.Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?Living with untreated prostate cancer: predictors of quality of life.miRNAs in tumor radiation response: bystanders or participants?How does active surveillance for prostate cancer affect quality of life? A systematic review.Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose-effect.Physicists' views on hadrontherapy: a survey of members of the Italian Association of Medical Physics (AIFM).Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions.Predicting toxicity in radiotherapy for prostate cancer.Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey.Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials.miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells."What if…": decisional regret in patients who discontinued active surveillance.
P50
Q27022847-23ABE5DA-AF65-43B3-8EAE-B73FE1F04DF1Q30823208-66C1F50B-2271-4D7D-996F-58304D0960BBQ30968067-9537F44D-27FC-4766-81F1-F8C09C75B78FQ34142419-F4C7BEDF-2EE9-4442-887B-A6793421FEA6Q34459761-8AB9FDF1-3B8E-4595-B7B1-7FE71C035FD0Q34952175-2E6FE92F-A66B-4E27-9F0C-6FBFE52DE9CFQ36323365-CEB18DA6-0297-4364-A693-DF19BB311211Q36544603-285C47D0-4C3C-40D8-A685-F11EEAE24692Q36619413-CBFAB41F-BE76-4EF1-97B3-024FDE465C44Q36965276-32E7FD8C-733E-4033-8F40-FB10DFAC9CF0Q37259793-7283256C-4AB5-49A6-9045-55B2F10CFB5CQ37526771-5C1DCEC1-74F6-4C34-8404-9584EF409930Q37526775-96B67EB3-2E29-40D7-A5D4-0BBBBC50AABCQ37547268-3D6F1AB8-7C77-4A88-BCFC-1BB6DEAA435EQ37593531-04940349-4F23-4D73-9769-F265BB626FC4Q37600136-1A4B9996-3BB6-4A19-B786-3CCF0CD66E43Q37706857-CBF0B26C-F9C5-4A9E-9E86-D111DADED83EQ38106626-6B7570FF-A2E3-46F0-8BBB-007D9A01A3EEQ38151298-D0377C67-62A5-4B65-88DA-F230262F9665Q38196652-CD90B0F2-0781-4ABA-825C-895A374E2CE9Q38242941-541C8D73-8450-4250-9CA3-F2514D076EDDQ38278154-B76EE981-FA97-4ED9-AA8B-AE6BB0087134Q38379465-A038C749-8DCB-4570-B122-579F7418651CQ38532568-2CACA13E-FB94-4E44-B1E3-36F9285A7950Q38615852-BE6ED0D6-DAC4-4B9B-8D0B-66BD9F07C54EQ38657673-6BE1918F-E12C-49DC-B9A4-EA983FC8EBECQ38663923-B6F63A43-505E-46A9-97A0-A599765B5E89Q38680195-7AD4A0C2-CF00-4133-B948-F63E55C41CAFQ38692621-6164C097-44E1-4B0F-BD4C-FA7B1914C169Q38706310-A9D340AE-3DC1-4665-BB84-186578845EE6Q38713064-1C35C94A-EC18-4DBD-A89A-C7D4B8B8359DQ38745925-0C69F259-35DF-46C2-88FC-A5648B93F925Q38805511-7584067C-40D0-45E9-989E-CBA7F702D441Q38807797-DE938AB8-F193-4FF1-9E06-D778DADE68E5Q38813319-5805FE14-59E7-4B00-A491-66CD8B786D95Q38832657-52062242-8762-4C64-BEC0-9491E4A455D3Q39023692-7E2F215A-74C4-43D8-9773-A87865F7F1C2Q39033358-1AD71105-528B-49FE-9470-5D2C232098C1Q39039757-8E53FAD1-E691-43DC-8170-FDB88E725697Q39311814-9E14F935-0752-4EB0-BA46-503D066D15BC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Riccardo Valdagni
@ast
Riccardo Valdagni
@en
Riccardo Valdagni
@es
Riccardo Valdagni
@nl
Riccardo Valdagni
@sl
type
label
Riccardo Valdagni
@ast
Riccardo Valdagni
@en
Riccardo Valdagni
@es
Riccardo Valdagni
@nl
Riccardo Valdagni
@sl
prefLabel
Riccardo Valdagni
@ast
Riccardo Valdagni
@en
Riccardo Valdagni
@es
Riccardo Valdagni
@nl
Riccardo Valdagni
@sl
P1053
K-1361-2016
P106
P1153
7003984247
P21
P31
P3829
P496
0000-0001-5140-9728